These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23974528)

  • 1. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.
    Vaziri ND
    Clin Exp Nephrol; 2014 Apr; 18(2):265-8. PubMed ID: 23974528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDL metabolism and activity in chronic kidney disease.
    Vaziri ND; Navab M; Fogelman AM
    Nat Rev Nephrol; 2010 May; 6(5):287-96. PubMed ID: 20308998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes of dysregulation of lipid metabolism in chronic renal failure.
    Vaziri ND
    Semin Dial; 2009; 22(6):644-51. PubMed ID: 20017835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.
    Rysz J; Gluba-Brzózka A; Rysz-Górzyńska M; Franczyk B
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of dyslipidemia of chronic renal failure.
    Vaziri ND; Moradi H
    Hemodial Int; 2006 Jan; 10(1):1-7. PubMed ID: 16441821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoproteins in chronic kidney disease: from bench to bedside.
    Speer T; Ridker PM; von Eckardstein A; Schunk SJ; Fliser D
    Eur Heart J; 2021 Jun; 42(22):2170-2185. PubMed ID: 33393990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease.
    Miljkovic M; Stefanovic A; Simic-Ogrizovic S; Vekic J; Bogavac-Stanojevic N; Cerne D; Kocbek P; Marc J; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
    Angiology; 2018 Nov; 69(10):861-870. PubMed ID: 29909653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction.
    Kaysen GA; Eiserich JP
    J Am Soc Nephrol; 2004 Mar; 15(3):538-48. PubMed ID: 14978155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein metabolism and CKD: overview.
    Barter P
    Clin Exp Nephrol; 2014 Apr; 18(2):243-6. PubMed ID: 24052157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
    Vaziri ND
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F262-72. PubMed ID: 16403839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
    Khoueiry G; Abdallah M; Saiful F; Abi Rafeh N; Raza M; Bhat T; El-Sayegh S; Kalantar-Zadeh K; Lafferty J
    Int Urol Nephrol; 2014 Jan; 46(1):27-39. PubMed ID: 23443874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Abnormal lipoprotein metabolism in CKD].
    Hirano T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1276-9. PubMed ID: 24288963
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypomagnesemia and atherogenic dyslipidemia in chronic kidney disease: surrogate markers for increased cardiovascular risk.
    Dey R; Rajappa M; Parameswaran S; Revathy G
    Clin Exp Nephrol; 2015 Dec; 19(6):1054-61. PubMed ID: 25697595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
    Kon V; Yang H; Fazio S
    Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.